Clinical trial

Carmustine Plus O(6)-Benzylguanine in Treating Patients With Recurrent or…

NCT00003348 · Duke University, Other · Completed

Key facts

NCT number NCT00003348
Title Carmustine Plus O(6)-Benzylguanine in Treating Patients With Recurrent or Progressive Gliomas of the Brain
Official title Phase I Trial of BCNU Plus O6-Benzylguanine in the Treatment of Patients With Recurrent, Persistent or Progressive Cerebral Anaplastic Gliomas
Lead sponsor Duke University, Other
Collaborators National Cancer Institute (NCI) NIH
Status Completed
Phase Phase 1
Study type Interventional
Conditions Brain and Central Nervous System Tumors
Intervention type Drug
Interventions O6-benzylguanine, carmustine
Enrollment 56
Start date May 1, 1998
Primary completion Aug 1, 2000
Completion Aug 1, 2000
First posted Aug 16, 2004
Last update posted Feb 20, 2013
Countries United States

At a glance

  • 1–9 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies